Quick Answer
IMPACT BIOMEDICAL INC. reported Total Revenue of $32.0 thousand for fiscal year 2025.
IMPACT BIOMEDICAL INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $32.0K | — | — | $50.0K | — |
| Revenue (ASC 606) | $32.0K | — | — | $50.0K | — |
| Net Income | -$11.84M +52.1% |
-$24.71M -469.8% |
-$4.34M +40.2% |
-$7.25M | — |
| Diluted EPS | -$0.38 +83.5% |
-$2.30 -3185.7% |
-$0.07 +30.0% |
-$0.10 | — |
| Total Assets | $17.41M -14.2% |
$20.29M -54.5% |
$44.63M -4.0% |
$46.50M | — |
| Cash and Equivalents | $3.0K -99.8% |
$2.00M +199800.0% |
$1.0K -50.0% |
$2.0K | — |
| Stockholders Equity | $12.61M +196.1% |
$4.26M -83.1% |
$25.22M -14.7% |
$29.56M -26.0% |
$39.92M |
| R&D Expense | $340.0K +22.3% |
$278.0K -83.5% |
$1.69M +37.4% |
$1.23M | — |
| Operating Income | -$4.28M +85.1% |
-$28.75M -613.8% |
-$4.03M -18.3% |
-$3.40M | — |
| Shares Outstanding | 104.62M +809.4% |
11.50M -90.8% |
125.07M +77.4% |
70.50M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $18.0K | — | +157.1% |
| Revenue (ASC 606) | September 30, 2025 | $18.0K | — | +157.1% |
| Net Income | September 30, 2025 | -$1.47M | -134.6% | +89.8% |
| Diluted EPS | September 30, 2025 | -$0.12 | -300.0% | +89.8% |
| Total Assets | September 30, 2025 | $18.21M | -61.0% | -4.5% |
| Cash and Equivalents | September 30, 2025 | $12.0K | -99.6% | -98.1% |
| Stockholders Equity | September 30, 2025 | -$11.81M | -137.7% | -14.2% |
| R&D Expense | September 30, 2025 | $52.0K | -36.6% | -30.7% |
| Operating Income | September 30, 2025 | -$948.0K | +15.9% | +17.8% |
| Shares Outstanding | September 30, 2025 | 12.19M | +5.9% | +0.0% |
- IMPACT BIOMEDICAL INC. reported Total Revenue of $32.0 thousand for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed a decrease of -36.0% in Total Revenue compared to the prior fiscal year.
- IMPACT BIOMEDICAL INC. reported Revenue (ASC 606) of $32.0 thousand for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed a decrease of -36.0% in Revenue (ASC 606) compared to the prior fiscal year.
- IMPACT BIOMEDICAL INC. reported Net Income of -$11.84 million for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed an increase of +52.1% in Net Income compared to the prior fiscal year.
- IMPACT BIOMEDICAL INC. reported Diluted EPS of $0.38 per share (loss) for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed an increase of +83.5% in Diluted EPS compared to the prior fiscal year.
- IMPACT BIOMEDICAL INC. reported Total Assets of $17.41 million for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed a decrease of -14.2% in Total Assets compared to the prior fiscal year.
- IMPACT BIOMEDICAL INC. reported Cash and Equivalents of $3.0 thousand for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed a decrease of -99.8% in Cash and Equivalents compared to the prior fiscal year.
- IMPACT BIOMEDICAL INC. reported Stockholders Equity of $12.61 million for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed an increase of +196.1% in Stockholders Equity compared to the prior fiscal year.
- IMPACT BIOMEDICAL INC. reported R&D Expense of $340.0 thousand for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed an increase of +22.3% in R&D Expense compared to the prior fiscal year.
- IMPACT BIOMEDICAL INC. reported Operating Income of -$4.28 million for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed an increase of +85.1% in Operating Income compared to the prior fiscal year.
- IMPACT BIOMEDICAL INC. reported Shares Outstanding of 104.62 million shares for fiscal year 2025.
- IMPACT BIOMEDICAL INC. showed an increase of +809.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: